SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about outcome of board meeting

06 Dec 2018 Evaluate

Alembic Pharmaceuticals has informed that the Board of Directors of the company at its meeting held today has approved the Issue of Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of up to Rs 500 crores on Private Placement Basis under a shelf disclosure document in multiple tranches; and constituted NCD Committee for issue and allotment of NCDs. The time of commencement of the Board Meeting was 12:30 pm and the time of conclusion was 1:30 pm.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×